168 related articles for article (PubMed ID: 21463982)
1. Dendritic cell generation and CD4+ CD25high FOXP3+ regulatory t cells in human head and neck carcinoma during radio-chemotherapy.
Schuler PJ; Börger V; Bölke E; Habermehl D; Matuschek C; Wild CA; Greve J; Bas M; Schilling B; Bergmann C; Trellakis S; Budach W; Gauler T; Brandau S; Lang S; Whiteside TL; Sorg RV; Hoffmann TK
Eur J Med Res; 2011 Feb; 16(2):57-62. PubMed ID: 21463982
[TBL] [Abstract][Full Text] [Related]
2. Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement.
Drennan S; Stafford ND; Greenman J; Green VL
Immunology; 2013 Nov; 140(3):335-43. PubMed ID: 23826668
[TBL] [Abstract][Full Text] [Related]
3. CD45RA-Foxp3high but not CD45RA+Foxp3low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression.
Sun W; Li WJ; Wu CY; Zhong H; Wen WP
J Exp Clin Cancer Res; 2014 Apr; 33(1):35. PubMed ID: 24761979
[TBL] [Abstract][Full Text] [Related]
4. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck.
Strauss L; Bergmann C; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Nov; 13(21):6301-11. PubMed ID: 17975141
[TBL] [Abstract][Full Text] [Related]
5. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment.
Strauss L; Bergmann C; Szczepanski M; Gooding W; Johnson JT; Whiteside TL
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4345-54. PubMed ID: 17671115
[TBL] [Abstract][Full Text] [Related]
6. Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
Schuler PJ; Harasymczuk M; Visus C; Deleo A; Trivedi S; Lei Y; Argiris A; Gooding W; Butterfield LH; Whiteside TL; Ferris RL
Clin Cancer Res; 2014 May; 20(9):2433-44. PubMed ID: 24583792
[TBL] [Abstract][Full Text] [Related]
7. Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer.
Strauss L; Bergmann C; Whiteside TL
Int J Cancer; 2007 Dec; 121(11):2473-83. PubMed ID: 17691114
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.
Schuler PJ; Schilling B; Harasymczuk M; Hoffmann TK; Johnson J; Lang S; Whiteside TL
Eur J Immunol; 2012 Jul; 42(7):1876-85. PubMed ID: 22585562
[TBL] [Abstract][Full Text] [Related]
9. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
10. Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Kitagawa T; Ueda E; Takenaka H; Kishimoto S
J Dermatol Sci; 2009 Apr; 54(1):31-7. PubMed ID: 19157789
[TBL] [Abstract][Full Text] [Related]
11. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer.
Schuler PJ; Harasymczuk M; Schilling B; Saze Z; Strauss L; Lang S; Johnson JT; Whiteside TL
Clin Cancer Res; 2013 Dec; 19(23):6585-96. PubMed ID: 24097865
[TBL] [Abstract][Full Text] [Related]
12. Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis.
Knitz MW; Bickett TE; Darragh LB; Oweida AJ; Bhatia S; Van Court B; Bhuvane S; Piper M; Gadwa J; Mueller AC; Nguyen D; Nangia V; Osborne DG; Bai X; Ferrara SE; Boss MK; Goodspeed A; Burchill MA; Tamburini BAJ; Chan ED; Pickering CR; Clambey ET; Karam SD
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883256
[TBL] [Abstract][Full Text] [Related]
13. Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis.
Wen YH; Lin HQ; Li H; Zhao Y; Lui VWY; Chen L; Wu XM; Sun W; Wen WP
Cancer Immunol Immunother; 2019 Feb; 68(2):221-232. PubMed ID: 30357458
[TBL] [Abstract][Full Text] [Related]
14. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression.
Mandapathil M; Lang S; Gorelik E; Whiteside TL
J Immunol Methods; 2009 Jul; 346(1-2):55-63. PubMed ID: 19450601
[TBL] [Abstract][Full Text] [Related]
15. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.
Sun W; Li WJ; Wei FQ; Wong TS; Lei WB; Zhu XL; Li J; Wen WP
Oncotarget; 2016 Jun; 7(25):37714-37727. PubMed ID: 27177223
[TBL] [Abstract][Full Text] [Related]
16. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck.
Chikamatsu K; Sakakura K; Whiteside TL; Furuya N
Head Neck; 2007 Feb; 29(2):120-7. PubMed ID: 17103408
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients.
Jie HB; Gildener-Leapman N; Li J; Srivastava RM; Gibson SP; Whiteside TL; Ferris RL
Br J Cancer; 2013 Nov; 109(10):2629-35. PubMed ID: 24169351
[TBL] [Abstract][Full Text] [Related]
18. Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer.
Schott AK; Pries R; Wollenberg B
Int J Mol Med; 2010 Jul; 26(1):67-75. PubMed ID: 20514424
[TBL] [Abstract][Full Text] [Related]
19. Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy.
Takahashi H; Sakakura K; Mito I; Ida S; Chikamatsu K
Cancer Sci; 2016 Aug; 107(8):1065-71. PubMed ID: 27228557
[TBL] [Abstract][Full Text] [Related]
20. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
Berntsen A; Brimnes MK; thor Straten P; Svane IM
J Immunother; 2010 May; 33(4):425-34. PubMed ID: 20386464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
